NASDAQ: GUTSFractyl Health Inc Stock
$6.70-0.02 (-0.3%)
Updated Apr 26, 2024
GUTS Price
$6.70
Fair Value Price
N/A
Market Cap
$320.78M
52 Week Low
$5.75
52 Week High
$14.50
P/E
-0.15x
P/B
-0.99x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$120.00k
Earnings
-$77.09M
Gross Margin
35.8%
Operating Margin
-64,242.5%
Profit Margin
-78,559.2%
Debt to Equity
-0.35
Operating Cash Flow
-$43M
Beta
1.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GUTS Overview
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GUTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GUTS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GUTS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
GUTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more GUTS due diligence checks available for Premium users.
Be the first to know about important GUTS news, forecast changes, insider trades & much more!
GUTS News
Valuation
GUTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.15x
Industry
14.88x
Market
41.14x
GUTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.99x
Industry
5.85x
GUTS's financial health
Profit margin
Revenue
$7.0k
Net Income
-$19.2M
Profit Margin
-335,857.1%
GUTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GUTS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$76.2M
Liabilities
$113.9M
Debt to equity
-0.35
GUTS's short-term assets ($35.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GUTS's long-term liabilities ($102.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GUTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GUTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.6M
Investing
-$136.0k
Financing
-$556.0k
GUTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GUTS vs Biotech Stocks
Fractyl Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.